Stefan Kovachev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefan Kovachev has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Miladin Stefanov Kovachev
Department of Obstetrics and Gynecology, Medical University
2 shared publicationsVictor Slavov
GENICA Genetic Medico-Diagnostic Laboratory, Sofia, Bulgaria
2 shared publicationsA. Ganovska
Department of General and Oncologic Gynecology , Military Medical Academy – Sofia , Bulgaria
1 shared publicationKremena Slavova
GENICA Genetic Medico‐Diagnostic Laboratory Sofia Bulgaria
1 shared publicationM. Kovachev
Medical University – Sofia , Bulgaria
1 shared publicationM. Kunchev
Virology Department , Military Medical Academy – Sofia , Bulgaria
1 shared publication
Latest Publications
- Open Access
- 1 March 2024
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 51 (1) , 25-29
Detection of predefined bacterial species in the Vaginal Microbiota in SARS-COV-2-Positive Patients
Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be found in the vagina of infected women remains unclear; moreover, the impact of the virus on the normal vaginal microbiota is not known. The aim: of our study was to identify the vaginal presence of SARS-CoV-2 and detection of predefined bacterial species changes in the vaginal flora of women that tested positive for SARS-CoV-2 infection. Materials and Methods.: This prospective study included 40 women, aged 24-47 years, tested for SARS-CoV-2 via nasopharyngeal and vaginal culture (TaqPath ™COVID-19 CE-IVD RT-PCR), and vaginally tested for changes in the vaginal microbiota using the Femoflor® 16 REAL-TIME PCR Detection Kit. Results.: No one of women in this study was tested positive for vaginal presence of SARS-CoV-2. Three (7.5%) women with sexually transmitted disease were excluded. Irregularities were observed in the vaginal microbiota of 8 (21.6%) out of 37 patients included in the study: 3 (8.1%) from the SARS-CoV-2-positive group and 5 (13.5%) from the SARS-CoV-2-negative group. The remaining 29 (78.4%) women had normal vaginal flora; lactobacilli were found to be dominant. Although results revealed a difference in the vaginal microbiota between the two groups, the differences were not statistically significant (p ≥ 0.05). Conclusions.: Even though it remains unclear whether SARS-CoV-2 invades the vagina of infected women, there is no significant evidence to suggest that it causes a more frequent disturbance in the vaginal microbiota of infected women compared to that in healthy women.
- 1 March 2024
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 51 (1) , 25-29
Open AccessDetection of predefined bacterial species in the Vaginal Microbiota in SARS-COV-2-Positive Patients
Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be found in the vagina of infected women remains unclear; moreover, the impact of the virus on the normal vaginal microbiota is not known. The aim: of our study was to identify the vaginal presence of SARS-CoV-2 and detection of predefined bacterial species changes in the vaginal flora of women that tested positive for SARS-CoV-2 infection. Materials and Methods.: This prospective study included 40 women, aged 24-47 years, tested for SARS-CoV-2 via nasopharyngeal and vaginal culture (TaqPath ™COVID-19 CE-IVD RT-PCR), and vaginally tested for changes in the vaginal microbiota using the Femoflor® 16 REAL-TIME PCR Detection Kit. Results.: No one of women in this study was tested positive for vaginal presence of SARS-CoV-2. Three (7.5%) women with sexually transmitted disease were excluded. Irregularities were observed in the vaginal microbiota of 8 (21.6%) out of 37 patients included in the study: 3 (8.1%) from the SARS-CoV-2-positive group and 5 (13.5%) from the SARS-CoV-2-negative group. The remaining 29 (78.4%) women had normal vaginal flora; lactobacilli were found to be dominant. Although results revealed a difference in the vaginal microbiota between the two groups, the differences were not statistically significant (p ≥ 0.05). Conclusions.: Even though it remains unclear whether SARS-CoV-2 invades the vagina of infected women, there is no significant evidence to suggest that it causes a more frequent disturbance in the vaginal microbiota of infected women compared to that in healthy women.
- Open Access
- 1 December 2022
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 49 (4) , 42-47
Lymph Node Metastases and Local Cancer Spread in Serous Endometrial Cancer and Endometrial Adenocarcinoma – A Retrospective Study
Serous endometrial carcinoma is characterized by its highly aggressive nature and represents about 10% of all endometrial carcinomas. It causes about 80% of deaths among women suffering from endometrial cancer. The aim of our study was to determine the frequency, lymphatic and local spread of serous endometrial cancer compared with endometrial adenocarcinoma. Materials and methods: This was a retrospective study conducted in a period of 4 years (from 2015 to 2019). One hundred and twenty-three women aged between 39 and 84 years suffering from endometrial carcinoma in various stages according to FIGO from stage I to IV were included in the study. Diagnosis was established clinically and by imaging studies and was histologically proven in all women. We performed radical hysterectomy type B or C (2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy) and pelvic lymph node dissection (PN) with or without paraaortic (PAR) lymph node dissection in all patients. Results : In 106 (86.2%) patients we found adenocarcinoma, in 9 (7.3%) of them – serous carcinoma, in 4 (3.3%) women – carcinosarcoma, in 4 (3.3%) women – clear cell carcinoma. The study compared the results only of 115 (100%) women with adenocarcinoma and serous carcinoma. In 17.8% of the patients with adenocarcinoma we found the presence of lymph node metastases, and in the group of patients with serous carcinoma we found lymph node metastases in 77.7% of them. There was a significant difference in the frequency of lymph node metastases according to the histological type EC (p < 0.00001). In 22.6% of patients with adenocarcinoma there was a local cancer spread, while such a spread was found in 66.7% of patients with serous cancer. After statistical processing of the results, we found a significant difference in the frequency of local tissue spread depending on the histological type of EC. Conclusion: Patients with serous endometrial cancer have significant more frequent lymphatic metastases and local spread than those with endometrial adenocarcinoma.
- 1 December 2022
- Published by Walter de Gruyter GmbH in Acta Medica Bulgarica
- Vol. 49 (4) , 42-47
Open AccessLymph Node Metastases and Local Cancer Spread in Serous Endometrial Cancer and Endometrial Adenocarcinoma – A Retrospective Study
Serous endometrial carcinoma is characterized by its highly aggressive nature and represents about 10% of all endometrial carcinomas. It causes about 80% of deaths among women suffering from endometrial cancer. The aim of our study was to determine the frequency, lymphatic and local spread of serous endometrial cancer compared with endometrial adenocarcinoma. Materials and methods: This was a retrospective study conducted in a period of 4 years (from 2015 to 2019). One hundred and twenty-three women aged between 39 and 84 years suffering from endometrial carcinoma in various stages according to FIGO from stage I to IV were included in the study. Diagnosis was established clinically and by imaging studies and was histologically proven in all women. We performed radical hysterectomy type B or C (2017 Update on the Querleu-Morrow Classification of Radical Hysterectomy) and pelvic lymph node dissection (PN) with or without paraaortic (PAR) lymph node dissection in all patients. Results : In 106 (86.2%) patients we found adenocarcinoma, in 9 (7.3%) of them – serous carcinoma, in 4 (3.3%) women – carcinosarcoma, in 4 (3.3%) women – clear cell carcinoma. The study compared the results only of 115 (100%) women with adenocarcinoma and serous carcinoma. In 17.8% of the patients with adenocarcinoma we found the presence of lymph node metastases, and in the group of patients with serous carcinoma we found lymph node metastases in 77.7% of them. There was a significant difference in the frequency of lymph node metastases according to the histological type EC (p < 0.00001). In 22.6% of patients with adenocarcinoma there was a local cancer spread, while such a spread was found in 66.7% of patients with serous cancer. After statistical processing of the results, we found a significant difference in the frequency of local tissue spread depending on the histological type of EC. Conclusion: Patients with serous endometrial cancer have significant more frequent lymphatic metastases and local spread than those with endometrial adenocarcinoma.
- 25 January 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (5) , 1489-1492
Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study
The objective of this study was to assess the endometrial pathology developed (EP) in postmenopausal women with genitourinary syndrome during and after vaginal oestrogen therapy. The 67 patients included were randomly grouped into group I underwent local oestrogen (oestriol) therapy and group II, underwent no therapy. Each patient’s medical history was taken and clinical and gynecological examination, with transvaginal ultrasound at the time of inclusion and during the control visits, was done. The study results show no statistically higher risk of EP for vaginal oestrogen therapy of genitourinary syndrome users compared to the non-users in menopause. No one atypical endometrial hyperplasia and endometrial intraepithelial neoplasia case during the study period was found.
- 25 January 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (5) , 1489-1492
Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study
The objective of this study was to assess the endometrial pathology developed (EP) in postmenopausal women with genitourinary syndrome during and after vaginal oestrogen therapy. The 67 patients included were randomly grouped into group I underwent local oestrogen (oestriol) therapy and group II, underwent no therapy. Each patient’s medical history was taken and clinical and gynecological examination, with transvaginal ultrasound at the time of inclusion and during the control visits, was done. The study results show no statistically higher risk of EP for vaginal oestrogen therapy of genitourinary syndrome users compared to the non-users in menopause. No one atypical endometrial hyperplasia and endometrial intraepithelial neoplasia case during the study period was found.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 2039-2049
A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients
The purpose of this review was to examine and summarize data for inosine pranobex (IP) immunotherapy in cervical HPV-positive patients. Persistent or recurring cervical human papillomavirus (HPV) infection is a major cause of cervical cancer. Self-clearance and blocking of cervical HPV infection depend on the status of the host immune system. Immunotherapy helps accelerate elimination of the infection. Host immunity is involved in the development of HPV infection. Several mechanisms of interaction between the virus and the immune system have been revealed; however, the mechanisms have not been completely elucidated. A properly functioning immune system impedes HPV progress and helps clear the pathogen from the body. IP has antiviral efficacy because it modulates both cellular and humoral immunities. IP has been on the market since 1971. Nevertheless, it has seldom been administered to treat cervical HPV infections. In this review, Google Scholar, PubMed/MEDLINE, Scopus, Cochrane Library, and Research Gate were searched for the period 1971– 2021. Prospective controlled trials, observational and retrospective studies, and meta-analysis and reviews on immunotherapy against HPV cervical infection were explored. Prior studies showed strong clinical efficacy of combined and standalone IP therapy in reversing HPV-induced changes in the cervix, preventing disease progression, and clearing the pathogen. IP treatment enhanced host antiviral activity against HPV, delayed or stopped cervical oncogenesis, and rapidly removed HPV from the body.
- 1 June 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 2039-2049
Open AccessA Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients
The purpose of this review was to examine and summarize data for inosine pranobex (IP) immunotherapy in cervical HPV-positive patients. Persistent or recurring cervical human papillomavirus (HPV) infection is a major cause of cervical cancer. Self-clearance and blocking of cervical HPV infection depend on the status of the host immune system. Immunotherapy helps accelerate elimination of the infection. Host immunity is involved in the development of HPV infection. Several mechanisms of interaction between the virus and the immune system have been revealed; however, the mechanisms have not been completely elucidated. A properly functioning immune system impedes HPV progress and helps clear the pathogen from the body. IP has antiviral efficacy because it modulates both cellular and humoral immunities. IP has been on the market since 1971. Nevertheless, it has seldom been administered to treat cervical HPV infections. In this review, Google Scholar, PubMed/MEDLINE, Scopus, Cochrane Library, and Research Gate were searched for the period 1971– 2021. Prospective controlled trials, observational and retrospective studies, and meta-analysis and reviews on immunotherapy against HPV cervical infection were explored. Prior studies showed strong clinical efficacy of combined and standalone IP therapy in reversing HPV-induced changes in the cervix, preventing disease progression, and clearing the pathogen. IP treatment enhanced host antiviral activity against HPV, delayed or stopped cervical oncogenesis, and rapidly removed HPV from the body.
- 14 March 2021
- Published by SAGE Publications in Urologia Journal
- Vol. 88 (4) , 348-354
The role of perioperative ureteral stenting for urologic complications in radical surgery of cervical cancer
This study aimed to establish the urologic complications of radical type C2 hysterectomy in cervical cancer patients with or without ureteral stenting. This prospective randomized study included 76 (100%) patients with clinically and pathologically established cervical cancer stages I and II treated with radical type C2 hysterectomy with pelvic lymph node dissection for the last 5 years (2014–2019). Patients were randomized into two groups (2:1 ratio): group II received perioperative ureteral stenting (n = 24, 31.6%) and group I did not (n = 52, 68.4%). Urologic complications observed during follow-up include intraoperative ureter and urinary bladder lesions and postoperative ureterovaginal and vesicovaginal fistulas. Of the 52 patients in group I who underwent surgery for cervical cancer, urologic complications were observed in 8 (10.5%) patients, 2 (2.6%) of whom underwent preoperative radiation therapy. In group II, urologic complications were observed in 2 (2.6%) patients, of which 1 (1.3%) received preoperative radiation therapy. Intraoperative urologic complications in group I (6.6%) included 3 (3.9%) ureteral lesions cases and 2 (2.6%) cases of urinary bladder lesions, wherein 1 patient received preoperative radiation therapy. One case of (1.3%) urinary bladder lesion was observed in group II. Postoperative complications were observed in 3 patients (3.9%) in group I, including 2 (2.6%) ureterovaginal fistula cases, wherein 1 (1.3%) patient received preoperative radiation therapy, and 1 (1.3%) case of vesicovaginal fistula. In group II, 1 (1.3%) patient who received perioperative radiotherapy developed postoperative vesicovaginal fistula. Urologic complications are extremely common during and after radical surgery (hysterectomy type C2) for cervical cancer. The cervical cancer stage had a significant effect on intra- and postoperative urologic complication rates in this study; however, no such effect was observed for preoperative radiation therapy and ureteral stenting, and significant differences were observed between the two study groups.
- 14 March 2021
- Published by SAGE Publications in Urologia Journal
- Vol. 88 (4) , 348-354
The role of perioperative ureteral stenting for urologic complications in radical surgery of cervical cancer
This study aimed to establish the urologic complications of radical type C2 hysterectomy in cervical cancer patients with or without ureteral stenting. This prospective randomized study included 76 (100%) patients with clinically and pathologically established cervical cancer stages I and II treated with radical type C2 hysterectomy with pelvic lymph node dissection for the last 5 years (2014–2019). Patients were randomized into two groups (2:1 ratio): group II received perioperative ureteral stenting (n = 24, 31.6%) and group I did not (n = 52, 68.4%). Urologic complications observed during follow-up include intraoperative ureter and urinary bladder lesions and postoperative ureterovaginal and vesicovaginal fistulas. Of the 52 patients in group I who underwent surgery for cervical cancer, urologic complications were observed in 8 (10.5%) patients, 2 (2.6%) of whom underwent preoperative radiation therapy. In group II, urologic complications were observed in 2 (2.6%) patients, of which 1 (1.3%) received preoperative radiation therapy. Intraoperative urologic complications in group I (6.6%) included 3 (3.9%) ureteral lesions cases and 2 (2.6%) cases of urinary bladder lesions, wherein 1 patient received preoperative radiation therapy. One case of (1.3%) urinary bladder lesion was observed in group II. Postoperative complications were observed in 3 patients (3.9%) in group I, including 2 (2.6%) ureterovaginal fistula cases, wherein 1 (1.3%) patient received preoperative radiation therapy, and 1 (1.3%) case of vesicovaginal fistula. In group II, 1 (1.3%) patient who received perioperative radiotherapy developed postoperative vesicovaginal fistula. Urologic complications are extremely common during and after radical surgery (hysterectomy type C2) for cervical cancer. The cervical cancer stage had a significant effect on intra- and postoperative urologic complication rates in this study; however, no such effect was observed for preoperative radiation therapy and ureteral stenting, and significant differences were observed between the two study groups.
- 19 May 2020
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 42 (4) , 314-318
Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization
Objective: To establish the clearance of cervical human papillomavirus (HPV) infection following postoperative immunotherapy with inosine pranobex in women receiving surgical treatment of established high-grade squamous intraepithelial lesion (HSIL) of the uterine cervix. Materials and methods: Over the six-year study period, 32 women with cervical HPV infection following electroconization (loop electrosurgical excision procedure) of the uterine cervix for established HSIL were randomly divided into two groups: I (n = 10) without and II (n = 22) with postoperative inosine pranobex immunotherapy. Follow-up after 24 and 48 months included cervical testing for HPV persistence and after 12, 24, and 48 months with cytology and colposcopy for dysplasia relapse (confirmed histologically). Results: Relapse monitoring in 32 women after 12 months revealed 1 and 0 HSIL positive in groups I and II, respectively; after 24 months an additional 3 patients in each group were positive; and after 48 months an additional 3 and 1 patients were positive in groups I and II, respectively (p < .05). The groups significantly differed (p < .05) with regard to clearing the most common high-risk HPV genotypes (HPV 16 and HPV 56). Conclusions: Inosine pranobex immunotherapy in HPV-positive patients following cervical conization significantly increased the clearance of viral infection with high-risk genotypes and reduced relapse of HSIL.
- 19 May 2020
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 42 (4) , 314-318
Immunotherapy in patients with local HPV infection and high-grade squamous intraepithelial lesion following uterine cervical conization
Objective: To establish the clearance of cervical human papillomavirus (HPV) infection following postoperative immunotherapy with inosine pranobex in women receiving surgical treatment of established high-grade squamous intraepithelial lesion (HSIL) of the uterine cervix. Materials and methods: Over the six-year study period, 32 women with cervical HPV infection following electroconization (loop electrosurgical excision procedure) of the uterine cervix for established HSIL were randomly divided into two groups: I (n = 10) without and II (n = 22) with postoperative inosine pranobex immunotherapy. Follow-up after 24 and 48 months included cervical testing for HPV persistence and after 12, 24, and 48 months with cytology and colposcopy for dysplasia relapse (confirmed histologically). Results: Relapse monitoring in 32 women after 12 months revealed 1 and 0 HSIL positive in groups I and II, respectively; after 24 months an additional 3 patients in each group were positive; and after 48 months an additional 3 and 1 patients were positive in groups I and II, respectively (p < .05). The groups significantly differed (p < .05) with regard to clearing the most common high-risk HPV genotypes (HPV 16 and HPV 56). Conclusions: Inosine pranobex immunotherapy in HPV-positive patients following cervical conization significantly increased the clearance of viral infection with high-risk genotypes and reduced relapse of HSIL.
- 28 October 2019
- Published by Springer Nature in Archives of Microbiology
- Vol. 202 (2) , 323-327
Cervical cancer and vaginal microbiota changes
Microbial changes in vaginal ecosystem may accelerate the process of cervical carcinogenesis. The developed cervical cancer can lead to changes in the vaginal microbiota. The aim of our study is to determine the vaginal microbiota changes at women with FIGO I stage cervical cancer. We conducted an open, single-site survey in the Department of Gynecology of the Military Medical Academy in Sofia, Bulgaria, from 2014 to 2019 year. The study included a total of 32 women aged 38–55 years with clinical and pathology established cervical cancer (FIGO I stage). The underlying vaginal DNA microbiological test indicated presence or absence of bacterial vaginosis, other vaginal infections or normal vaginal microbiota. Of 32 (100%) women enrolled in our study, 19 (59.4%) was with FIGO IA stage cervical cancer and 13 (40.6%) with IB stage. Disturbances of vaginal microbiota in we found at 23 (71.9%) of women with cervical cancer included in our study. At the rest of 9 (28.1%) women we found out normal vaginal microbiota. Bacterial vaginosis was determined clinically and microbiologically in 15 (46.9%) women enrolled in the study. Aerobic vaginitis caused by Streptococcus species we establish at 4 (12.5%) of women. Trichomonas vaginalis infection have 1 (3.1%) women and Candida Albicans the last one 1 (3.1%) from this group with disturbed vaginal microbial balance. Bacterial dysbacteriosis, characterized by a predominance of Gardnerella vaginalis alone or in complex with other anaerobic bacteria, aerobic vaginitis and other sexually transmitted vaginal pathogens from one side and a concomitant paucity of vaginal Lactobacillus species may be an HPV-dependent cofactor for cervical neoplasia development. Only with this single observation it is difficult to confirm that vaginal microbiota dysbiosis contributes to HPV infection and carcinogenesis.
- 28 October 2019
- Published by Springer Nature in Archives of Microbiology
- Vol. 202 (2) , 323-327
Cervical cancer and vaginal microbiota changes
Microbial changes in vaginal ecosystem may accelerate the process of cervical carcinogenesis. The developed cervical cancer can lead to changes in the vaginal microbiota. The aim of our study is to determine the vaginal microbiota changes at women with FIGO I stage cervical cancer. We conducted an open, single-site survey in the Department of Gynecology of the Military Medical Academy in Sofia, Bulgaria, from 2014 to 2019 year. The study included a total of 32 women aged 38–55 years with clinical and pathology established cervical cancer (FIGO I stage). The underlying vaginal DNA microbiological test indicated presence or absence of bacterial vaginosis, other vaginal infections or normal vaginal microbiota. Of 32 (100%) women enrolled in our study, 19 (59.4%) was with FIGO IA stage cervical cancer and 13 (40.6%) with IB stage. Disturbances of vaginal microbiota in we found at 23 (71.9%) of women with cervical cancer included in our study. At the rest of 9 (28.1%) women we found out normal vaginal microbiota. Bacterial vaginosis was determined clinically and microbiologically in 15 (46.9%) women enrolled in the study. Aerobic vaginitis caused by Streptococcus species we establish at 4 (12.5%) of women. Trichomonas vaginalis infection have 1 (3.1%) women and Candida Albicans the last one 1 (3.1%) from this group with disturbed vaginal microbial balance. Bacterial dysbacteriosis, characterized by a predominance of Gardnerella vaginalis alone or in complex with other anaerobic bacteria, aerobic vaginitis and other sexually transmitted vaginal pathogens from one side and a concomitant paucity of vaginal Lactobacillus species may be an HPV-dependent cofactor for cervical neoplasia development. Only with this single observation it is difficult to confirm that vaginal microbiota dysbiosis contributes to HPV infection and carcinogenesis.
- 12 March 2018
- Published by Wiley in Journal of Medical Virology
- Vol. 90 (6) , 1142-1149
Prevalence of human papillomavirus infection in women in Bulgaria: A 2017 update
The distribution and prevalence of 33 high‐, medium‐, and low‐risk HPV genotypes were surveyed in women aged between 15 and 54 years and with normal cytology in the biggest cities and regions in Bulgaria (viz., Sofia, Plovdiv, Varna, and Burgas) and in two smaller communities (viz., Pleven and Vidin). This survey was also intended to update previous data collected in 2012 and to assess the results of a national campaign to immunize all 12‐year‐old girls against HPV, which was also started in 2012. The GenoFlow HPV Array Test Kit was used to analyze HPV status in cervical samples collected in 2012‐2016 from 5277 women who had visited 47 gynecological clinics across the study sites. HPV infection was confirmed in 1570 (29.8%). The most common infecting genotype was HPV‐16, which was detected in 687 women (13%), followed by HPV‐56 in 333 women (6.3%), HPV‐33 in 209 cases (4%), and HPV‐31 in 190 subjects (3.6%). This is the second study to assess the prevalence of HPV infection in larger Bulgarian cities including the capital and to draw attention to the unusually high proportion of specific infecting genotypes.
- 12 March 2018
- Published by Wiley in Journal of Medical Virology
- Vol. 90 (6) , 1142-1149
Prevalence of human papillomavirus infection in women in Bulgaria: A 2017 update
The distribution and prevalence of 33 high‐, medium‐, and low‐risk HPV genotypes were surveyed in women aged between 15 and 54 years and with normal cytology in the biggest cities and regions in Bulgaria (viz., Sofia, Plovdiv, Varna, and Burgas) and in two smaller communities (viz., Pleven and Vidin). This survey was also intended to update previous data collected in 2012 and to assess the results of a national campaign to immunize all 12‐year‐old girls against HPV, which was also started in 2012. The GenoFlow HPV Array Test Kit was used to analyze HPV status in cervical samples collected in 2012‐2016 from 5277 women who had visited 47 gynecological clinics across the study sites. HPV infection was confirmed in 1570 (29.8%). The most common infecting genotype was HPV‐16, which was detected in 687 women (13%), followed by HPV‐56 in 333 women (6.3%), HPV‐33 in 209 cases (4%), and HPV‐31 in 190 subjects (3.6%). This is the second study to assess the prevalence of HPV infection in larger Bulgarian cities including the capital and to draw attention to the unusually high proportion of specific infecting genotypes.
- 18 September 2017
- Published by Morressier GmbH
OVARIAN FUNCTION AFTER RADICAL HYSTERECTOMY FOR CERVICAL CANCER WITH OVARIAN TRANSPOSITION
- 18 September 2017
- Published by Morressier GmbH
OVARIAN FUNCTION AFTER RADICAL HYSTERECTOMY FOR CERVICAL CANCER WITH OVARIAN TRANSPOSITION